From Diagnosis to Immunotherapy: Translational Pathways and Bottlenecks of Organic Luminescent Materials in Urothelial Carcinoma
Year: 2026
Type: article
Abstract: Bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) share three stubborn clinical problems: carcinoma in situ (CIS) is hard to find, residual lesions after transurethral resection of bladder tumor (TURBT) are easy to miss, and patients who do not respond to bacillus Calmette–Guérin (BCG) have few effective bladder-sparing options. The bladder and ureter are natural lumens that endoscopy can reach, which gives us an anatomical foothold for combining molecular detection, intraoperative navigation, and local therapy. This review follows how organic luminescent materials have moved from photodynamic diagnosis (PDD) to photoimmunotherapy (PIT), and looks at where clinical translation currently stands and what still blocks it. PDD improves CIS detection—several clinical studies support this—but false positives and the poor tissue penetration of blue light keep its use narrow. In the first-in-human trial of a Nectin-4-targeted fluorescent probe, biopsy diagnostic accuracy reached 96.0%, a sign that molecular imaging-guided surgery has entered clinical validation. On the therapeutic side, antibody–photoabsorber conjugates can selectively kill membrane-marker-positive tumor cells, and when paired with immune checkpoint inhibitors, they show promise in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). Insufficient tissue penetration, limited target specificity, and the absence of standardized light dosimetry remain the core barriers to translation. NIR-II imaging and activatable theranostic agents are likely to be the most important future directions.
Source: Molecules
Institutions: Tianjin First Center Hospital, Tianjin Medical University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Keywords: organic luminescent materials, urothelial carcinoma, bladder cancer, upper tract urothelial carcinoma, photodynamic diagnosis, photoimmunotherapy, nectin-4, fluorescent probes, surgical navigation, BCG-unresponsive bladder cancer, non-muscle-invasive bladder cancer, immune checkpoint inhibitors, NIR-II imaging, light dosimetry, tissue penetration
Open Access status: gold
Estimated APC paid: $3,258
Award: G2712340309
OpenAlex ID: W7236709314
